Blood
Articles in this Issue
circFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing <i>TNS1</i> mRNA in megakaryocytes
Abstract During thrombopoiesis, megakaryocytes (MKs) transform their cytoplasm into proplatelets through complex cytoskeletal rearrangements. The shear force of blood flow releases...
Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy
Abstract Ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), 2 B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell (CAR-T) therapies,...
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor
Abstract The treatment landscape for chronic lymphocytic leukemia (CLL) has been transformed by the advent of covalent Bruton tyrosine kinase (BTK) inhibitors (cBTKis) and B-cell l...
Time for iMDSCs: off-the-shelf MDSCs to control GVHD
Enhancer heterogeneity in acute lymphoblastic leukemia drives differential gene expression in patients
Abstract Genetic alterations alone cannot account for the diverse phenotypes of cancer cells. Even cancers with the same driver mutation show significant transcriptional heterogene...
A newcomer in allosteric therapy for Ph+ leukemias
Leukemic fusion: partners and mutations shape <i>NUP98</i> r leukemia
RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT
Abstract RGI-2001, a glycolipid that binds CD1d receptor of antigen-presenting cells, can activate invariant natural killer T (NKT) cells and stimulate cytokine-dependent prolifera...
Designing a strong bridge to CAR-T cells with bispecifics
KSHV/HHV8-positive germinotropic lymphoproliferative disorder in a patient with HIV
The iNKT-Treg axis in GVHD control
Thrombopoiesis comes full circle
Preclinical characterization of TGRX-678, a brain-penetrant allosteric inhibitor of BCR::ABL1
Abstract Clinical resistance or intolerance to tyrosine kinase inhibitors remains challenging for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positi...
Fusion oncoproteins and cooperating mutations define disease phenotypes in <i>NUP98</i> -rearranged leukemia
Abstract Leukemias with NUP98 rearrangements exhibit heterogeneous phenotypes such as acute myeloid leukemia, T-cell acute lymphoblastic leukemia (T-ALL), or myelodysplastic syndro...
Patient-specific enhancers in genetically uniform leukemias
A novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic <i>MADD</i> variants
Abstract The regulated secretion of von Willebrand factor (VWF) from Weibel-Palade bodies (WPBs) in endothelial cells is fundamental to hemostasis. This process relies on recruitin...
MADDlessness may cause von Willebrand disease type 1
Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease
Abstract Front-line pharmaceutical interventions for treating acute graft-versus-host disease (GVHD) are not uniformly effective and have toxic side effects. Myeloid-derived suppre...
Chilling controversy: cold-stored platelets for prophylactic transfusions
Abstract The US Food and Drug Administration recently licensed 14-day cold-stored platelets for bleeding patients. This policy change represents a reversal from the 1970s when cold...